Leukemia:CXCR4的过度激活驱动慢性淋巴细胞白血病的发生发展

2021-08-10 xiaozeng MedSci原创

CXCR4是一种G蛋白偶联受体,其可调节造血干细胞的稳态、骨髓的生成、淋巴细胞的生成以及驱使免疫细胞向其配体CXCL12接近的趋向作用。

CXCR4是一种G蛋白偶联受体,其可调节造血干细胞的稳态、骨髓的生成、淋巴细胞的生成以及驱使免疫细胞向其配体CXCL12接近的趋向作用。

既往研究显示,CXCL12的结合可诱导多种G蛋白依赖性和非依赖性信号通路,包括PI3K/AKT、MAPK/ERK和PLC/Ca2+信号通路。而异常的CXCR4活性与淋巴瘤的发生发展以及治疗抗性相关。

在该研究中,研究人员构建了具有CXCR4信号过度激活的功能获得性CXCR4突变(CXCR4 C1013G)小鼠模型,并鉴定CXCR4为多个关键致癌途径的关键激活因子。


研究人员发现,CXCR4的过度激活会导致过渡型B1淋巴细胞的扩增,其是慢性淋巴细胞白血病(CLL)的前体细胞。在小鼠Eμ-TCL1 CLL模型中,CXCR4的过度激活会导致疾病发作的显著加速并出现更具侵略性的表型。

CXCR4过度激活信号的转录特征的鉴定

进一步的研究发现,过度激活的CXCR4信号能够与TCL1协同作用,在B细胞中诱导独特的致癌转录程序,其特征表现为PLK1/FOXM1相关信号通路的激活。相应地,Eμ-TCL1 CXCR4 C1013G B细胞表现出Richter综合征患者相关转录特征的富集,这是CLL的一种侵袭性转化状态。


值得注意的是,在侵袭性淋巴瘤中,MYC的激活与CXCR4的表达水平升高相关。一致的是,在Eμ-Myc小鼠模型(一种侵袭性B细胞癌模型)中,额外的过度激活的CXCR4信号并不影响生存率。

CXCR4和TCL1的共激活介导B细胞中独特的致癌转录程序

总而言之,该研究结果表明,CXCR4的过度激活是侵袭性淋巴瘤表型的一个共同驱动因素。


原始出处:

Lewis, R., Maurer, H.C., Singh, N. et al. CXCR4 hyperactivation cooperates with TCL1 in CLL development and aggressiveness. Leukemia (06 August 2021).

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1998018, encodeId=ec7c1998018be, content=<a href='/topic/show?id=75ff66001cd' target=_blank style='color:#2F92EE;'>#淋巴细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66001, encryptionId=75ff66001cd, topicName=淋巴细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Mon Jun 20 11:26:37 CST 2022, time=2022-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030821, encodeId=877c203082158, content=<a href='/topic/show?id=71353e8964f' target=_blank style='color:#2F92EE;'>#发生发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37896, encryptionId=71353e8964f, topicName=发生发展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=wgsun, createdTime=Thu Feb 03 03:26:37 CST 2022, time=2022-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008864, encodeId=296d100886425, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=88c25254749, createdName=147ec62cm09(暂无昵称), createdTime=Tue Aug 17 23:44:36 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302394, encodeId=07971302394cb, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Thu Aug 12 13:26:37 CST 2021, time=2021-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412464, encodeId=aa621412464aa, content=<a href='/topic/show?id=c5d95546ff' target=_blank style='color:#2F92EE;'>#CXCR4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5546, encryptionId=c5d95546ff, topicName=CXCR4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8c832868137, createdName=chenwq09, createdTime=Thu Aug 12 13:26:37 CST 2021, time=2021-08-12, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1998018, encodeId=ec7c1998018be, content=<a href='/topic/show?id=75ff66001cd' target=_blank style='color:#2F92EE;'>#淋巴细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66001, encryptionId=75ff66001cd, topicName=淋巴细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Mon Jun 20 11:26:37 CST 2022, time=2022-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030821, encodeId=877c203082158, content=<a href='/topic/show?id=71353e8964f' target=_blank style='color:#2F92EE;'>#发生发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37896, encryptionId=71353e8964f, topicName=发生发展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=wgsun, createdTime=Thu Feb 03 03:26:37 CST 2022, time=2022-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008864, encodeId=296d100886425, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=88c25254749, createdName=147ec62cm09(暂无昵称), createdTime=Tue Aug 17 23:44:36 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302394, encodeId=07971302394cb, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Thu Aug 12 13:26:37 CST 2021, time=2021-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412464, encodeId=aa621412464aa, content=<a href='/topic/show?id=c5d95546ff' target=_blank style='color:#2F92EE;'>#CXCR4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5546, encryptionId=c5d95546ff, topicName=CXCR4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8c832868137, createdName=chenwq09, createdTime=Thu Aug 12 13:26:37 CST 2021, time=2021-08-12, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1998018, encodeId=ec7c1998018be, content=<a href='/topic/show?id=75ff66001cd' target=_blank style='color:#2F92EE;'>#淋巴细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66001, encryptionId=75ff66001cd, topicName=淋巴细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Mon Jun 20 11:26:37 CST 2022, time=2022-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030821, encodeId=877c203082158, content=<a href='/topic/show?id=71353e8964f' target=_blank style='color:#2F92EE;'>#发生发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37896, encryptionId=71353e8964f, topicName=发生发展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=wgsun, createdTime=Thu Feb 03 03:26:37 CST 2022, time=2022-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008864, encodeId=296d100886425, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=88c25254749, createdName=147ec62cm09(暂无昵称), createdTime=Tue Aug 17 23:44:36 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302394, encodeId=07971302394cb, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Thu Aug 12 13:26:37 CST 2021, time=2021-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412464, encodeId=aa621412464aa, content=<a href='/topic/show?id=c5d95546ff' target=_blank style='color:#2F92EE;'>#CXCR4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5546, encryptionId=c5d95546ff, topicName=CXCR4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8c832868137, createdName=chenwq09, createdTime=Thu Aug 12 13:26:37 CST 2021, time=2021-08-12, status=1, ipAttribution=)]
    2021-08-17 147ec62cm09(暂无昵称)

    学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1998018, encodeId=ec7c1998018be, content=<a href='/topic/show?id=75ff66001cd' target=_blank style='color:#2F92EE;'>#淋巴细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66001, encryptionId=75ff66001cd, topicName=淋巴细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Mon Jun 20 11:26:37 CST 2022, time=2022-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030821, encodeId=877c203082158, content=<a href='/topic/show?id=71353e8964f' target=_blank style='color:#2F92EE;'>#发生发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37896, encryptionId=71353e8964f, topicName=发生发展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=wgsun, createdTime=Thu Feb 03 03:26:37 CST 2022, time=2022-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008864, encodeId=296d100886425, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=88c25254749, createdName=147ec62cm09(暂无昵称), createdTime=Tue Aug 17 23:44:36 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302394, encodeId=07971302394cb, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Thu Aug 12 13:26:37 CST 2021, time=2021-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412464, encodeId=aa621412464aa, content=<a href='/topic/show?id=c5d95546ff' target=_blank style='color:#2F92EE;'>#CXCR4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5546, encryptionId=c5d95546ff, topicName=CXCR4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8c832868137, createdName=chenwq09, createdTime=Thu Aug 12 13:26:37 CST 2021, time=2021-08-12, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1998018, encodeId=ec7c1998018be, content=<a href='/topic/show?id=75ff66001cd' target=_blank style='color:#2F92EE;'>#淋巴细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66001, encryptionId=75ff66001cd, topicName=淋巴细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Mon Jun 20 11:26:37 CST 2022, time=2022-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030821, encodeId=877c203082158, content=<a href='/topic/show?id=71353e8964f' target=_blank style='color:#2F92EE;'>#发生发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37896, encryptionId=71353e8964f, topicName=发生发展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=wgsun, createdTime=Thu Feb 03 03:26:37 CST 2022, time=2022-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008864, encodeId=296d100886425, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=88c25254749, createdName=147ec62cm09(暂无昵称), createdTime=Tue Aug 17 23:44:36 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302394, encodeId=07971302394cb, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Thu Aug 12 13:26:37 CST 2021, time=2021-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412464, encodeId=aa621412464aa, content=<a href='/topic/show?id=c5d95546ff' target=_blank style='color:#2F92EE;'>#CXCR4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5546, encryptionId=c5d95546ff, topicName=CXCR4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8c832868137, createdName=chenwq09, createdTime=Thu Aug 12 13:26:37 CST 2021, time=2021-08-12, status=1, ipAttribution=)]
    2021-08-12 chenwq09

相关资讯

Ann Clin Transl Neurol:CXCR4受体激动剂可在坐骨神经损伤后刺激轴突的再生

本研究旨在检验坐骨神经被挤压/切割后信号轴CXCL12α-CXCR4是否被激活,并检验新型CXCR4激动剂NUCC-390在促进神经损伤恢复方面的活性,研究结果已在线发表于Ann Clin

CohBar发现CXCR4的新型肽抑制剂,CXCR4是肿瘤生长和转移的关键调节因子

CohBar是一家临床阶段生物技术公司,致力于开发基于线粒体的疗法(MBT)来治疗慢性疾病并延长寿命。该公司发现了一系列新型的线粒体肽类似物,它们具有强大的体外活性,可作为CXC趋化因子受体4型(CXCR4)的选择性抑制剂,并且在黑素瘤小鼠模型中具有初步的体内功效。CXCR4是涉及肿瘤生长,侵袭,血管生成,转移和对治疗的抵抗力的关键调节受体。

Blood:GPRASP蛋白是造血干细胞移植的重要负性调控因子

中心点:GPRASP家族成员负性调节小鼠HSC体内的造血再生活性。GPRASP家族成员调控CXCR4的稳定性和转运,从而影响HSC的存活、静止、归巢和壁龛保留摘要:造血干细胞移植(HSCT)常被用来治疗血液病。供体HSCs必须在重建生态位的破坏环境中存活、增殖和分化。阐明移植HSCs活性的分子机制将有助于改善HSCT的预后。Gprasp1或Gprasp2基因沉默可增加移植后造血干细胞和祖细胞(HS

Blood:Cxcr4功能获得性突变导致滤泡外免疫反应失控!

Cxcr4脱敏在B细胞活化和浆细胞分化过程中具有关键作用,微调Cxcr4信号对限制滤泡外免疫反应的强度和持续时间均至关重要

CLIN CANCER RES:CXCR4是PET/CT诊断巴雷特食管和食管癌的潜在靶标

巴雷特食管是导致食管癌的早期癌变阶段。巴雷特食管可以通过内镜进行检查和诊断,但目前因缺少特异性的标志,影像学起到的作用有限。在巴雷特食管和食管癌进展中慢性炎症和多种趋化因子通路起到了重要作用。